 NEW YORK, March 11, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization CRO, providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohns disease patients. 